TY - JOUR
T1 - World federation of societies of biological psychiatry guidelines for the pharmacological treatment of dementias in primary care
AU - WFSBP Task Force on Mental Disorders in Primary Care
AU - WFSBP Task Force on Dementia
AU - Ihl, Ralf
AU - Bunevicius, Robertas
AU - Frölich, Lutz
AU - Winblad, Bengt
AU - Schneider, Lon S.
AU - Dubois, Bruno
AU - Burns, Alistair
AU - Thibaut, Florence
AU - Kasper, Siegfried
AU - Möller, Hans Jürgen
AU - Baranska-Rybak, Wioletta
AU - Cubała, Wiesław Jerzy
AU - Harro, Jaanus
AU - Pop, Victor J.M.
AU - Rancans, Elmars
AU - Rasmussen, Jill
AU - Rihmer, Zoltan
AU - Saravane, Djea
AU - Schlaepfer, Thomas E.
AU - Sher, Leo
AU - Tang, S. W.
AU - Valius, Leonas
AU - Wong, David
AU - Zhitnikova, Larisa M.
AU - Zohar, Joseph
AU - Benoit, Michel
AU - Blesa, Rafael
AU - Brodaty, Henry
AU - Colimon, Nancy
AU - Degrell, Islwan
AU - DeKosky, Steve
AU - Eker, Engin
AU - Endo, Hidetoshi
AU - Erkinjuntti, Timo
AU - Förstl, Hans
AU - Frisoni, Giovanni
AU - Gauthier, Serge
AU - Giacobini, Ezio
AU - Gomez-Isla, Teresa
AU - Goufries, Carl Gerhard
AU - Grundman, Michael
AU - Han, Changsu
AU - Hock, Christoph
AU - Kulaksizoglu, Isin Baral
AU - Marksteiner, Josef
AU - Masters, Colin
AU - McKeith, Ian
AU - Olofsdottir, Maria
AU - Rainer, Michael
AU - Reisberg, Barry
N1 - Funding Information:
Lon Schneider has received grants from the NIH P50 AG05142, R01 AG033288, and R01 AG037561, the State of California, the Alzheimer’s Association for a registry for dementia and cognitive impairment trials and grant or research support from Baxter, Genentech, Johnson & Johnson, Eli Lilly, Novartis, and Pfizer. He discloses that within the last 3 years, he has served as a consultant for and received consulting fees from Abbvie Laboratories, AC Immune, Allon, AstraZeneca, Baxter, Biogen Idec, Biotie, Bristol-Myers Squibb, Elan, Eli Lilly, EnVivo, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Merck, Novartis, Piramal, Pfizer, Roche, Sanofi, Servier, Takeda, Tau Rx, Toyama, and Zinfandel; and in the past from Ipsen and Schwabe. Florence Thibaut has no conflict of interest to declare.
Publisher Copyright:
© 2015 Informa Healthcare.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Objective. To define a practice guideline for biological treatment of dementias for general practitioners in primary care. Methods. TThis paper is a short and practical summary of the World Federation of Biological Psychiatry (WFSBP) guidelines for the Biological treatment of Alzheimer's disease and other dementias for treatment in primary care (Ihl et al. 2011). The recommendations were developed by a task force of international experts in the field and arc based on randomized controlled studies. Results. Anti-dementia medications neither cure, nor arrest, or alter the course of the disease. The type of dementia, the individual symptom constellation and the tolerability and evidence for efficacy should determine what medications should be used. In treating neuropsychiatrie symptoms, psychosocial intervention should be the treatment of first choice. For neuropsychiatrie symptoms, medications should only be considered when psychosocial interventions are not adequate and after cautious risk-benefit analysis. Conclusions. Depending on the diagnostic entity and clinical presentation different anti-dementia drugs can be recommended. These guidelines provide a practical approach for general practitioners managing dementias.
AB - Objective. To define a practice guideline for biological treatment of dementias for general practitioners in primary care. Methods. TThis paper is a short and practical summary of the World Federation of Biological Psychiatry (WFSBP) guidelines for the Biological treatment of Alzheimer's disease and other dementias for treatment in primary care (Ihl et al. 2011). The recommendations were developed by a task force of international experts in the field and arc based on randomized controlled studies. Results. Anti-dementia medications neither cure, nor arrest, or alter the course of the disease. The type of dementia, the individual symptom constellation and the tolerability and evidence for efficacy should determine what medications should be used. In treating neuropsychiatrie symptoms, psychosocial intervention should be the treatment of first choice. For neuropsychiatrie symptoms, medications should only be considered when psychosocial interventions are not adequate and after cautious risk-benefit analysis. Conclusions. Depending on the diagnostic entity and clinical presentation different anti-dementia drugs can be recommended. These guidelines provide a practical approach for general practitioners managing dementias.
KW - Alzheimer's disease
KW - Anti-dementia drugs
KW - Dementia
KW - Guidelines
KW - Lewy body disease
KW - Neuropsychiatric symptoms
UR - http://www.scopus.com/inward/record.url?scp=84924036336&partnerID=8YFLogxK
U2 - 10.3109/13651501.2014.961931
DO - 10.3109/13651501.2014.961931
M3 - Review article
C2 - 25195764
AN - SCOPUS:84924036336
SN - 1365-1501
VL - 19
SP - 2
EP - 7
JO - International Journal of Psychiatry in Clinical Practice
JF - International Journal of Psychiatry in Clinical Practice
IS - 1
ER -
